NTLA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA
Portfolio Pulse from
Rosen Law Firm is pursuing a securities class action lawsuit against Intellia Therapeutics (NTLA) for allegedly misleading investors about its Phase 1/2 study for NTLA-3001. The lawsuit claims the company failed to disclose that viral-based editing demand was declining, potentially impacting the program's viability. Investors who purchased NTLA securities between July 30, 2024, and January 8, 2025, are encouraged to join the class action by April 14, 2025.
April 10, 2025 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Securities class action lawsuit could negatively impact investor confidence in Intellia Therapeutics' clinical development strategy and transparency.
The lawsuit alleges material non-disclosure about the viability of NTLA-3001, which could erode investor trust and potentially lead to stock price decline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100